Literature DB >> 20673233

Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.

Gavin Wright1, Lorette Noiret, Steven W M Olde Damink, Rajiv Jalan.   

Abstract

Hepatic encephalopathy complicates the course of both acute and chronic liver disease and its treatment remains an unmet clinical need. Ammonia is thought to be central in its pathogenesis and remains an important target of current and future therapeutic approaches. In liver failure, the main detoxification pathway of ammonia metabolism is compromised leading to hyperammonaemia. In this situation, the other ammonia-regulating pathways in multiple organs assume important significance. The present review focuses upon interorgan ammonia metabolism in health and disease describing the role of the key enzymes, glutamine synthase and glutaminase. Better understanding of these alternative pathways are leading to the development of new therapeutic approaches.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20673233     DOI: 10.1111/j.1478-3231.2010.02302.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  41 in total

1.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

Review 2.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 3.  Pathophysiology, diagnosis, and management of hepatic encephalopathy.

Authors:  Christopher Sheasgreen; Lucy Lu; Ameen Patel
Journal:  Inflammopharmacology       Date:  2014-10-10       Impact factor: 4.473

4.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

5.  Analysis of cerebral blood flow and intracranial hypertension in critical patients with non-hepatic hyperammonemia.

Authors:  Alexandre Sanches Larangeira; Marcos Toshiyuki Tanita; Marcos Antonio Dias; Olavo Franco Ferreira Filho; Vinicius Daher Alvares Delfino; Lucienne Tibery Queiroz Cardoso; Cintia Magalhães Carvalho Grion
Journal:  Metab Brain Dis       Date:  2018-05-03       Impact factor: 3.584

6.  Hypothesis: role for ammonia neutralization in the prevention and reversal of heart failure.

Authors:  Oscar H L Bing
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-03-16       Impact factor: 4.733

7.  Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.

Authors:  Manuela Merli; Michela Giusto; Cristina Lucidi; Valerio Giannelli; Ilaria Pentassuglio; Vincenza Di Gregorio; Barbara Lattanzi; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2012-12-07       Impact factor: 3.584

Review 8.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

9.  Expression, purification, and characterization of mouse glycine N-acyltransferase in Escherichia coli.

Authors:  Daniel R Dempsey; Jason D Bond; Anne-Marie Carpenter; Santiago Rodriguez Ospina; David J Merkler
Journal:  Protein Expr Purif       Date:  2014-02-25       Impact factor: 1.650

10.  Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.

Authors:  Filipe S Cardoso; Michelle Gottfried; Shannan Tujios; Jody C Olson; Constantine J Karvellas
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.